N-Acetylcysteine: The Four EP Specified Impurities, Their Sources, and Analytical Methods Explained

N-Acetylcysteine (NAC) is probably one of the most easily "underestimated" old drugs. This expectorant, which entered clinical use in the mid-1960s, is now active simultaneously in emergency rooms (as an antidote for acetaminophen poisoning), respiratory clinics (for chronic bronchitis, COPD, and other mucus-related diseases), and a large number of ongoing antioxidant mechanism studies. But for those doing API quality control, reference standard purchasing, or registration filings, the truly "mind-bending" part of NAC is often not its pharmacology, but its impurity profile, which is easy to misread.

CAS: 616-91-1

One Molecule, Three Identities

N-Acetylcysteine first entered clinical use as an expectorant in the mid-1960s, and from the mid-1970s became the first-line antidote for acetaminophen (paracetamol) poisoning, for which its intravenous formulation was included in the WHO Model List of Essential Medicines. Its pharmacological logic can be summarized in three layers:

• Expectorant: the free sulfhydryl group (-SH) in the molecule can break the disulfide bonds between sputum mucins, reducing sputum viscosity and making it easier to cough up;

• Detoxification: as a precursor of cysteine, NAC can raise intracellular glutathione (GSH) levels, and glutathione is precisely the key substance for clearing NAPQI, the toxic metabolite of acetaminophen;

• Antioxidant: glutathione itself is an important intracellular antioxidant, which is also why NAC has been widely used in recent years in studies related to oxidative stress.

It is worth noting that recent reviews have pointed out that the classic "sulfhydryl reducing agent + glutathione precursor" model of NAC may not fully explain all of its pharmacological effects, and the hydrogen sulfide and sulfur-containing species generated during its in vivo transformation may be the true mechanism behind some of its antioxidant and cytoprotective effects — a reminder that even for a drug used for sixty years, its mechanism of action is still being re-understood.

EP Monograph 0967: Who Exactly Are Impurities A, B, C, and D?

For APIs and formulations, European Pharmacopoeia (Ph. Eur.) monograph 0967 is one of the most frequently cited standards for NAC quality control, stipulating that the content of the API calculated on the dried basis must be between 98.0% and 101.0%, and explicitly listing four "specified impurities":

⚠ Note: the internal catalog numbers 35, 36, and 38 correspond to European Pharmacopoeia impurities B, D, and C respectively, not in alphabetical order; when ordering, it is recommended to confirm by CAS number to avoid selection errors.

The pharmacopoeial HPLC method is performed at 220 nm, with an NAC main peak retention time of about 6.4 minutes, impurity C at about 12 minutes, and impurity D at about 14 minutes. The system suitability requirement is that the resolution between impurities A and B is not less than 1.5, and between impurities C and D not less than 2.0 — this is also the step where many laboratories most easily "stumble" during method transfer.

Where Do These Impurities Come From?

An impurity profile is not listed arbitrarily; each impurity corresponds to a specific degradation or process pathway:

• Impurity A (L-cystine): essentially a symmetric disulfide formed by oxidative coupling of two molecules of L-cysteine, the most typical oxidative/storage degradation product of sulfhydryl-containing APIs, whose formation is accelerated by exposure to oxygen, trace metals, or unsuitable pH;

• Impurity B (L-cysteine): under acidic conditions, the amide bond (N-C bond) on the NAC molecule undergoes hydrolytic cleavage to form free cysteine, making it the most common hydrolytic degradation product;

• Impurities C and D: respectively correspond to by-products caused by incomplete selectivity in the acetylation reaction — the former (N,N'-diacetyl-L-cystine) is a symmetric disulfide formed by oxidative dimerization of two NAC molecules, and studies on the stability of NAC parenteral nutrition formulations have specifically examined the effect of oxygen exposure on its formation; the latter (N,S-diacetyl-L-cysteine) is a process-related impurity from additional acetylation on the sulfur atom.

This also explains why the storage conditions for sulfhydryl-containing APIs and impurities are generally strict (mostly 2℃–8℃ or -20℃±5℃ cold-chain storage): the free sulfhydryl group is extremely easily oxidized by air, and the entire process from synthesis, to sub-packaging, to transportation of reference standards must avoid this risk.

Why Is NAC Impurity Analysis Always a Difficulty in Method Development?

Quantitative analysis of NAC and its related impurities is not easy. As early as 2000, a methodological study by Toussaint et al. from the University of Liège, Belgium, published in the Journal of Chromatography A, pointed out that cysteine and its derivatives tend to co-elute under conventional UV detection conditions, making accurate distinction and quantification difficult, and usually requiring additional confirmation by detection techniques such as mass spectrometry.

At the same time, to maintain the stability of sulfhydryl-containing analytes in the mobile phase and avoid secondary oxidation during analysis, chromatographic methods usually need to maintain acidic conditions. This also means that, in the absence of reliable impurity reference standards, it is difficult to confirm the true identity of unknown peaks based solely on chromatographic retention times and theoretical structure speculation, let alone complete method validation and impurity quantification.

From 4 Specified Impurities to 85 Related Structures: CATO's N-Acetylcysteine Reference Standard System

Around the practical needs of NAC impurity analysis, CATO has established a reference standard system covering the four specified impurities of the European Pharmacopoeia (EP), which can meet the needs of method development, analytical method validation, process research, and production release at different stages, and supports in-stock supply.

The four specified impurities above are only part of CATO's N-acetylcysteine reference standard system. At present, around NAC-related research, CATO has established a reference standard library covering about 85 related structures, including:

• Process-related impurities and degradation products (such as the N-acetylcysteine impurity 9–71 series);

• Stereoisomers and homologs, such as N-acetyl-D-cysteine, DL-homocystine, and D-homocysteine, for screening analytical interference from structurally similar impurities;

• Salt forms and derivatives, including hydrochloride, trifluoroacetate, and disodium salts, to meet the analytical needs of different existing forms in stability studies;

• Isotope-labeled internal standards, such as DL-homocysteine-d4, for method establishment and internal standard correction in LC-MS/MS quantitative analysis.

As a reference material manufacturer accredited by both CNAS (RM0030) and ANAB (AR-2832) and compliant with ISO 17034, CATO confirms the structure and purity of all reference standards through multiple analytical techniques including HPLC, NMR, and MS, and provides COA and spectral data. The value assignment uncertainty of the products is controlled within ±2.0% (95% CI); routine products are available in stock with same-day shipping, and special structures support custom synthesis.

References

1. European Pharmacopoeia, Monograph 0967, Acetylcysteine.http://www.uspbpep.com/ep60/acetylcysteine%200967e.pdf (Note: this is a public mirror of the EP 6.0 version text; the current official text should be consulted via the EDQM subscription database pheur.edqm.eu for access)

2. Toussaint B, Pitti C, Streel B, Ceccato A, Hubert P, Crommen J. Quantitative analysis of N-acetylcysteine and its pharmacopeial impurities in a pharmaceutical formulation by liquid chromatography–UV detection–mass spectrometry. Journal of Chromatography A. 2000;896(1-2):191-199.https://pubmed.ncbi.nlm.nih.gov/11093654/ | DOI: https://doi.org/10.1016/S0021-9673(00)00741-X

3. Elizabeth MM, Ravi A, Rameshwar N, Sudheer M, Krishnamurthy B. Development and validation of an analytical method for related substances in N-acetyl-L-cysteine effervescent tablets by RP-HPLC. Indian Journal of Pharmaceutical Education and Research. 2017;51(4):626-635.https://www.ijper.org/article/51/4/626.pdf

4. Pedre B, Barayeu U, Ezeriņa D, Dick TP. The mechanism of action of N-acetylcysteine (NAC): The emerging role of H2S and sulfane sulfur species. Pharmacology & Therapeutics. 2021 Dec;228:107916.https://pubmed.ncbi.nlm.nih.gov/34171332/ | DOI: https://doi.org/10.1016/j.pharmthera.2021.107916

5. Santus P, Signorello JC, Danzo F, Lazzaroni G, Saad M, Radovanovic D. Anti-inflammatory and anti-oxidant properties of N-acetylcysteine: a fresh perspective. Journal of Clinical Medicine. 2024;13(14):4127.https://pmc.ncbi.nlm.nih.gov/articles/PMC11278452/ | DOI: https://doi.org/10.3390/jcm13144127

6. DrugBank Online. Acetylcysteine (DB06151).https://go.drugbank.com/drugs/DB06151

7. Sommer I, Schwebel H, Adamo V, Bonnabry P, Bouchoud L, Sadeghipour F. Stability of N-acetylcysteine (NAC) in standardized pediatric parenteral nutrition and evaluation of N,N-diacetylcystine (DAC) formation. Nutrients. 2020;12(6):1849.https://pubmed.ncbi.nlm.nih.gov/32575864/ | DOI: https://doi.org/10.3390/nu12061849

8. WHO Model List of Essential Medicines, 23rd list (2023). Section 4.2, Antidotes and other substances used in poisonings — Acetylcysteine injection (added to the EML in 1999).https://list.essentialmeds.org/recommendations/1293 | https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.02